Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT02652780
REVERSE
Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation.
Type: Interventional
Status of the trial: Completed
Orphan Drug Recognition: No
Inclusion
- Opening Date: 2016-02-01
- Closing Date: 2017-08-01
Criteria
Inclusion: Patients with Leber hereditary optic neuropathy (LHON) carrying the m.11778G>A mitochondrial DNA mutationcarrying the m.11778G>A mitochondrial DNA mutation
Exclusion: Disease duration of more than one year in one or both eyes
Children: Yes
Adults: Yes
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Workgroups
Neuro-Ophthalmology Rare Diseases (WG2)
This ERN is supported by:
